Alpha Tau Secures Major U.S. Prostate Cancer Commercialization Deal with Tolmar, Including $35M Upfront and $20M Premium Equity Investment
DRTS has more than doubled off its 52-week low of $2.81 on elevated volume (1.9× avg).
Summary
Alpha Tau Medical has entered a strategic collaboration with Tolmar for exclusive U.S. commercialization rights of Alpha DaRT for prostate cancer, securing $35 million upfront and up to $161.5 million in milestones, alongside a $20 million equity investment at a premium.
Key Events · M&A and Partnerships · DRTS
-
Exclusive U.S. Commercialization Rights Granted
Alpha Tau granted Tolmar exclusive U.S. commercialization rights for Alpha DaRT in prostate cancer, with an option to expand into bladder cancer.
-
Significant Upfront Capital Infusion
Tolmar will provide $35 million in upfront payments, comprising a $15 million manufacturing investment and a $20 million equity investment at a 25% premium to the 30-day VWAP.
-
Substantial Milestone Payment Potential
Alpha Tau is eligible for up to $161.5 million in clinical, regulatory, and commercial milestone payments for the prostate cancer indication.
-
Favorable Revenue Sharing Agreement
Alpha Tau will receive 60% of net sales from Tolmar for the supply of Alpha DaRT.
Analysis · DRTS · Industrial Applications And Services
This collaboration is a significant commercialization milestone for Alpha Tau's Alpha DaRT therapy, providing a clear path to market in the substantial U.S. prostate cancer segment through an experienced partner, Tolmar. The deal brings immediate financial benefits with $35 million in upfront payments, including a $20 million equity investment at a 25% premium, demonstrating strong external confidence in the technology. The potential for substantial milestone payments and a favorable revenue-sharing agreement further strengthens Alpha Tau's financial position and validates its platform technology, building on recent positive clinical data.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 43.9% of the 578 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.54%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, DRTS was trading at $9.24 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $785.9M. The 52-week trading range was $2.81 to $11.62. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.